227 results on '"Miguel, J.F. San"'
Search Results
2. PS1366 TISSUE ENGINEERING OF AN ORTHOTOPIC HUMANIZED BONE-ORGAN AS A PLATFORM FOR PRECLINICAL MULTIPLE MYELOMA RESEARCH
3. Primary Plasma Cell Leukemia: Clinical, Immunophenotypic, DNA Ploidy, and Cytogenetic Characteristics
4. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders
5. P-234 Mesenchymal stromal cells from MDS with 5q- show different genetic and epigenetic changes compared to those from other low-risk MDS
6. Analysis of Zoledronic ACID Therapy for Patients with Multiple Myeloma with Asymptomatic Biochemical Relaps.
7. 65 Simultaneous analysis of the expression of 14 genes with individual prognostic value in patients with MDS at diagnosis
8. 258 Down-regulation of DICER1, DROSHA and microRNAs in MSC from MDS compared to healthy controls
9. 78 A small subset of mesenchymal stem cells from MDS patients harbour the cytogenetic abnormality of haematopoietic cells
10. Zalypsis Has Synergistic Effect When Combined with Bortezomib + Dexamethasone through Caspase Dependent and Mainly Independent Mechanisms and through A Potent Induction of DNA Damage
11. Long Term Significance of Response in Multiple Myeloma After Stem Cell Transplantation.
12. Value of Gene Expression Profiling by Taqman® Low Density Arrays in the Diagnosis and Prognosis of Acute Myeloid Leukemia.
13. Bortezomib (Velcade)-Melphalan-Prednisone (VMP) Versus Velcade- Thalidomide-Prednisone (VTP) in Elderly Untreated Multiple Myeloma Patients: Which Is the Best Partner for Velcade: An Alkylating or An Immunomodulator Agent?
14. Both Expanded and Uncultured Mesenchymal Stem Cells from MDS Patients Are Genomically Abnormal, Showing a Specific Genetic Profile for the 5q- Syndrome.
15. Final Results of a Phase II Trial with Plitidepsin (Aplidin) Alone and in Combination with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
16. DNA Double Strand Breaks Induction by Zalypsis, a Novel Marine Compound, Results in Potent Antimyeloma Activity
17. Thalidomide/Dexamethasone (TD) Vs. Bortezomib(Velcade®)/Thalidomide/Dexamethasone (VTD) Vs. VBMCP/VBAD/Velcade® As Induction Regimens Prior Autologous Stem Cell Transplantation (ASCT) in Younger Patients with Multiple Myeloma (MM): First Results of a Prospective Phase III PETHEMA/Gem Trial
18. A High Number of Losses in 13q14 Chromosome Is Associated with a Worse Outcome and Biological Differences in Patients with B Chronic Lymphoid Leukemia.
19. Effect of Pre and Post-Transplantation Responses on Outcome of Multiple Myeloma Patients: CR and near-CR Should Not Be Considered as Equivalent Prognostic Markers. Results of a PETHEMA/Gem Prospective Study
20. Triple Combinations of the HDAC Inhibitor Panobinostat (LBH589) + Dexamethasone with Either Lenalidomide or Bortezomib Are Highly Effective in a Multiple Myeloma Mouse Model.
21. Mesenchymal Stem Cells from Patients with Myelodysplastic Syndromes Are Functionally and Genomically Abnormal.
22. Antimyeloma Efficacy of Plitidepsin (Aplidin®): From Bench to the Bedside.
23. Prognostic Value of Immunophenotyping of Multiple Myeloma: A Study on 685 Patients Uniformly Treated with High-Dose Therapy.
24. Presence of DRB1*01 Allele in Multiple Myeloma Patients Is Associated with Indolent Disease.
25. Effect of Mesenchymal Stem Cells on the Viability, Proliferation and Differentiation of B Lymphocytes.
26. MMY-3002: A Phase 3 Study Comparing Bortezomib-Melphalan-Prednisone (VMP) with Melphalan-Prednisone (MP) in Newly Diagnosed Multiple Myeloma.
27. Maintenance Treatment after Autologous Peripheral Blood Stem Cell Transplantation (PBSCT) in Multiple Myeloma (MM) with a Unique Weekly Dose of Pegylated Interpheron alpha2b (Pegintron®): Preliminary Clinical Results in 30 Patients of a Phase II Multicentric Study.
28. The Activation of Fas Receptor by APO010, a Recombinant Form of Fas Ligand, Induces In Vitro and In Vivo Antimyeloma Activity.
29. Clinical Efficacy of Bortezomib Based Therapy in Plasma Cell Leukemias.
30. Non Myeloablative Allogeneic Related Transplant in Patients with Aggressive B Cell Lymphoma: Results of Two Multicenter Spanish Trials. The GELTAMO Group.
31. Clinical Prognostic Factors in Chemosensitive Multiple Myeloma (MM) Patients Intensified with High Dose Therapy/Stem Cell Support (HDT/SCS): Results of the Spanish Trial (PETHEMA/GEM2000).
32. Imatinib Mesilate Modifies Genes Involved in Hematopoiesis in Non Clonal Bone Marrow Cells from CML Patients in Complete Cytogenetic Response.
33. The IGF1-R Inhibitor AEW541 Is a Potent Anti-Myeloma Agent That Overcomes Drugs Resistance, and Has Synergistic Activity with Other New Drugs.
34. New Criteria To Identify Risk of Progression in Monoclonal Gammopathy of Uncertain Significance: Multiparametric Flow Cytometry Analysis of Bone Marrow Plasma Cells.
35. Deep Vein Thrombosis in Myeloma: Estimate of Prevelance and Recommendations for Therapy Based upon a Survey of Members of the International Myeloma Working Group (IMWG).
36. Proteasome Inhibitor Bortezomib Has Antitumour Activity Against Both CD34 Negative and CD34 Positive Acute Myeloid Leukemia Cells.
37. A Waldenström’s Macroglobulinemia Case with Functional Class Switch Recombination.
38. Identification of Neoplastic Infiltration of the Cerebrospinal Fluid (CSF) in Patients with Aggressive B-Cell Non-Hodgkin’s Lymphoma (B-NHL) without Clinical Evidence of Leptomeningeal Disease: A Comparative Analysis of the Utility of Flow Cytometry (FCM) Versus Conventional Cytology (CC).
39. Role of c-Kit in Multiple Myeloma.
40. Relapse-Risk Stratification in Acute Promyelocytic Leukemia Patients by PML-RARa Transcript Quantification.
41. Minimal Residual Disease Monitoring after Reduced Intensity Conditioning (RIC) Allogeneic Transplantation: May Help To Individualize Post-Transplant Immunotherapeutic Strategies.
42. ZHX2, CHC1L and RAN Gene Expression Levels Determine Different Prognosis Groups in Multiple Myeloma (MM) Patients.
43. Reduced Intensity Conditioning Unrelated Transplant Plus Cyclosporine and MMF as GVHD Prophylaxis: Results of a Prospective Study.
44. A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma (MM) Patients.
45. Frequency, Characteristics, and Reversibility of Peripheral Neuropathy (PN) in the APEX Trial.
46. Analysis of Both Clonal Functional and Non-Functional Immunoglobulin Heavy Chain (IgH) Rearrangements in Waldenström’s Macroglobulinemia.
47. Genetic Abnormalities and Patterns of Antigenic Expression in Multiple Myeloma.
48. A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (V-MP) in Elderly Untreated Multiple Myeloma Patients.
49. Molecular Characterization in Hairy Cell Leukemia (HCL): Rearrangement Analysis of Heavy Chain in Immunoglobulin Genes (IgH).
50. The Cell Expression of PML-RARa at Diagnosis Has a Marginal Correlation with Prognosis in Patients with Acute Promyelocytic Leukemia (APL).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.